MEI Pharma (NASDAQ:MEIP) posted its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01), Zacks reports. The company had revenue of $2.05 million during the quarter, compared to the consensus estimate of $3.05 million. MEI Pharma had a negative net margin of 2,508.05% and a negative return on equity of 71.32%.
MEIP stock traded up $0.02 during mid-day trading on Friday, reaching $2.71. The company had a trading volume of 283,019 shares, compared to its average volume of 160,452. The company has a market cap of $192.76 million, a price-to-earnings ratio of -3.66 and a beta of 1.92. MEI Pharma has a 52 week low of $1.82 and a 52 week high of $5.14.
A number of research firms have weighed in on MEIP. restated a “buy” rating and issued a $7.50 price target on shares of MEI Pharma in a research note on Friday, November 9th. HC Wainwright began coverage on MEI Pharma in a research note on Thursday, December 20th. They issued a “buy” rating and a $10.00 price target for the company. BidaskClub downgraded MEI Pharma from a “hold” rating to a “sell” rating in a research note on Friday, October 12th. Finally, Zacks Investment Research downgraded MEI Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $8.08.
TRADEMARK VIOLATION WARNING: “MEI Pharma (MEIP) Announces Earnings Results” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2019/02/09/mei-pharma-meip-announces-earnings-results.html.
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Recommended Story: Stochastic Momentum Index (SMI)
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.